Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: The potential as a new asthma medication

Muraki, Masato; Imbe, Shu; Sakakibara, Ryuji; Ikeda, Yoko; Yamagata, Shigeyoshi; Iwanaga, Takashi; Tohda, Yuji

doi:10.1016/j.intimp.2009.08.007

Cited by 14 publications

(6 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] The pharmacological effects of CysLT are conducted through two types of membrane receptorsCysLTR1 and CysLTR2 -which are coupled to protein-G. 18 Remarkably, these receptors were primarily described at the level of lung mucosa and intestinal mucosa at the ileum and colon. 19 In many diseases affecting lung and intestinal mucosa, such as asthma and interstitial cystitis, the use of montelukast, a selective antagonist of CysLTR1, minimizes the effects of these pathologies, probably through the inhibition of cytosolic Ca 2+ .…”

Section: M M U N O L O G Y O R I G I N a L A R T I C L Ementioning

confidence: 99%

Leukotriene C4 prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance

Álvarez¹,

Amaral²,

Langellotti³

et al. 2011

Immunology

View full text Add to dashboard Cite

Summary Leukotriene C4 is an important mediator in the development of inflammatory reactions and ischaemia. Previous studies have shown that leukotriene C4 is able to modulate the function of dendritic cells (DCs) and induce their chemotaxis from skin to lymph node. In this study, we decided to evaluate the modulation exerted by leukotriene C4 on DCs, depending on their status of activation. We showed for the first time that leukotriene C4 stimulates endocytosis both in immature and lipopolysaccharide (LPS) ‐activated DCs. Moreover, it suppressed the interleukin‐12p70 (IL‐12p70) release, but induces the secretion of IL‐23 by DCs activated with LPS and promotes the expansion of T helper type 17 (Th17) lymphocytes. Furthermore, blocking the release of IL‐23 reduced the percentages of CD4+ T cells producing IL‐17 in a mixed lymphocyte reaction. Ours results suggest that leukotriene C4 interferes with the complete maturation of inflammatory DCs in terms of phenotype and antigen uptake, while favouring the release of IL‐23, the main cytokine involved in the maintenance of the Th17 profile.

show abstract

Section: M M U N O L O G Y O R I G I N a L A R T I C L Ementioning

confidence: 99%

Leukotriene C4 prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance

Álvarez¹,

Amaral²,

Langellotti³

et al. 2011

Immunology

View full text Add to dashboard Cite

show abstract

“…The authors concluded that leukotriene receptor antagonists might contribute to the management of ocular inflammatory response. Outside the eye, inhaled montelukast could significantly inhibit the bronchoconstriction induced by LTC4 and LTD4 with no injury to the lung tissue in an animal model of asthma [97] and this demonstrates the therapeutic effectiveness and safety of locally applied montelukast.…”

Section: The Use Of Leukotriene Antagonists Drugs In the Treatment Ofmentioning

confidence: 66%

Anti-Leukotrienes in the treatment of allergic conjunctivitis and comorbidities in children: An update

et al. 2016

View full text Add to dashboard Cite

The term "Allergy" actually includes a variety of different diseases (rhinitis, conjunctivitis, asthma, urticaria, and dermatitis) with a common pathological basis linked to the release of chemical mediators such as histamine, platelet-activating factor, arachidonic acid metabolites, and chemotactic factors secreted by mastocytes, basophils, and eosinophils. The key-role of leukotrienes (LTs) as mediators in allergic and inflammatory response justifies possible therapeutic use of leukotriene antagonists in other allergic diseases beyond asthma. LTs modifiers reduce asthma symptoms, short-acting beta2-antagonist (SABA) use, and asthma exacerbations, and improve all indexes of pulmonary function, as measured by the increases in forced expiratory flow at one second (FEV1), peak expiratory flow (PEF), quality of life, and indices of bronchial inflammation (blood eosinophils, inflammatory cells in the bronchial mucosa, exhaled nitric oxide, substance P, neurokinin A, eosinophil cationic protein, and serum myeloperoxidase). Anti-LTs have also been successfully used by some authors to control allergic diseases such as rhinitis, atopic dermatitis, chronic urticaria and allergic conjuncitivitis. Moreover, recently, new reports have been published concerning other conditions (migraine prophylaxis, sleep disorders, inflammatory bowel disease, and nasal polyposis) that broaden the future range of clinical applications. Topical ocular montelukast can be a potential therapeutic drug with a new route of administration that can be used for treatment of allergic conjunctivitis.

show abstract

“…Since Since LTRAs have bronchodilatory as well as anti-inflammatory effects, intravenous montelukast was developed as a medication to relieve acute asthma [96] and inhalant montelukast was developed to directly deliver medications to the airway [97]. Although these forms of montelukast exert significant anti-asthmatic effects, they have not yet been marketed.…”

Section: Resultsmentioning

confidence: 99%

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma

Matsuse

Kohno

2013

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

IntroductionThe prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve as alternatives or add-on drugs. Several issues such as predicted responses, effects of peripheral airway and airway remodeling and alternative administration routes remain to be clarified before LTRAs PAGE 3 could serve a more effective role in the treatment of asthma. Areas covered

show abstract

Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: The potential as a new asthma medication

Cited by 14 publications

References 28 publications

Leukotriene C4 prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance

Leukotriene C4 prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance

Anti-Leukotrienes in the treatment of allergic conjunctivitis and comorbidities in children: An update

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma

Contact Info

Product

Resources

About